Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $701.7 million.

  • Protagonist Therapeutics' Liabilities and Shareholders Equity rose 1620.1% to $701.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 3177.38%. This contributed to the annual value of $744.7 million for FY2024, which is 10805.22% up from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' Liabilities and Shareholders Equity is $701.7 million, which was up 1620.1% from $718.0 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Liabilities and Shareholders Equity registered a high of $744.7 million during Q4 2024, and its lowest value of $239.9 million during Q1 2023.
  • Its 5-year average for Liabilities and Shareholders Equity is $453.4 million, with a median of $358.0 million in 2023.
  • Per our database at Business Quant, Protagonist Therapeutics' Liabilities and Shareholders Equity tumbled by 3113.39% in 2023 and then surged by 16235.36% in 2024.
  • Protagonist Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $347.7 million in 2021, then dropped by 28.69% to $247.9 million in 2022, then skyrocketed by 44.38% to $358.0 million in 2023, then soared by 108.05% to $744.7 million in 2024, then decreased by 5.78% to $701.7 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $701.7 million for Q3 2025, versus $718.0 million for Q2 2025 and $742.1 million for Q1 2025.